TABLE 1.

Demographic characteristics of included participants with Parkinson’s disease.

Group	M1 group (n = 9)	DLPFC group (n = 9)	Cerebellum group (n = 9)	Sham group (n = 9)	P value
Age (years)	54.20 ± 4.1	50.09 ± 2.4	61.30 ± 7.9	58.30 ± 8.0	0.60
Gender (M/F)	8/1	6/3	2/7	3/6	<0.01
H&Y stage	1.89 ± 0.6	1.67 ± 0.5	2.13 ± 0.6	1.78 ± 0.7	0.75
More affected side (L/R)	2/7	1/8	2/7	1/8	0.85
Duration of diagnosed (months)	93.54 ± 68.2	73.81 ± 39.2	49.11 ± 39.3	100.18 ± 147.0	0.43
UPDRS	33.22 ± 13.1	25.56 ± 17.0	24.22 ± 9.9	23.44 ± 14.7	0.48
MMSE	28.11 ± 1.8	28.89 ± 1.8	27.33 ± 2.2	28.89 ± 2.0	0.29
LEDD (mg)	592.1 ± 208.2	603.89 ± 357.3	468.22 ± 212.1	426.11 ± 243.7	0.41

M, male; F, female; H&Y, Hoehn and Yahr stage; L, left; R, right; MMSE, Mini-Mental State Examination; LEDD: levodopa equivalent daily dosage.